Skip to Content
Merck
CN

EHU126521

MISSION® esiRNA

targeting human SGMS1

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGGCTGGTGAATGACACATAACAGCTGTACAAAGTGGGGAAAAGACAAATTGTCCGAAGTGCTAAGAACTCCATGAGAGAAGATGCCATAAAATAAACACCTCCCTAATCCTATTATCTTTCAATGGTTACCTTGACTTAACCTATTGAGTTACCTGGTCAGCACTGTGATCTTTTTTTCTCTCCAAAGGACCTGCGTTGGACAACAAT

Ensembl | human accession no.

ENSG00000198964

NCBI accession no.

NM_147156

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... SGMS1(259230), SGMS1(259230)

Related Categories

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
DYT

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Haofeng Lu et al.
Cancer chemotherapy and pharmacology, 87(2), 217-228 (2020-11-24)
The survival benefit of sorafenib, the most used drug for advanced hepatocellular carcinoma (HCC), is unsatisfactory due to the development of adaptive resistance. Exploring the mechanisms underlying sorafenib resistance is important to develop sensitizing strategy. Sphingomyelin synthase (SMS) plays a
Yun-Chi Tang et al.
Cancer research, 77(19), 5272-5286 (2017-08-05)
Aneuploidy, a hallmark of cancer cells, poses an appealing opportunity for cancer treatment and prevention strategies. Using a cell-based screen to identify small molecules that could selectively kill aneuploid cells, we identified the compound N-[2-hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl]-decanamide monohydrochloride (DL-PDMP), an antagonist of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service